JP2007511539A5 - - Google Patents

Download PDF

Info

Publication number
JP2007511539A5
JP2007511539A5 JP2006540034A JP2006540034A JP2007511539A5 JP 2007511539 A5 JP2007511539 A5 JP 2007511539A5 JP 2006540034 A JP2006540034 A JP 2006540034A JP 2006540034 A JP2006540034 A JP 2006540034A JP 2007511539 A5 JP2007511539 A5 JP 2007511539A5
Authority
JP
Japan
Prior art keywords
aat
composition
concentration
pharmaceutical composition
antioxidant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006540034A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007511539A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/038650 external-priority patent/WO2005048985A2/en
Publication of JP2007511539A publication Critical patent/JP2007511539A/ja
Publication of JP2007511539A5 publication Critical patent/JP2007511539A5/ja
Pending legal-status Critical Current

Links

JP2006540034A 2003-11-14 2004-11-11 α１−抗トリプシン組成物およびこのような組成物を用いた処置方法 Pending JP2007511539A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52054903P 2003-11-14 2003-11-14
PCT/US2004/038650 WO2005048985A2 (en) 2003-11-14 2004-11-11 Alpha 1-antitrypsin compositions and treatment methods using such compositions

Publications (2)

Publication Number Publication Date
JP2007511539A JP2007511539A (ja) 2007-05-10
JP2007511539A5 true JP2007511539A5 (https=) 2007-12-27

Family

ID=34619481

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006540034A Pending JP2007511539A (ja) 2003-11-14 2004-11-11 α１−抗トリプシン組成物およびこのような組成物を用いた処置方法

Country Status (12)

Country Link
US (2) US20080312136A1 (https=)
EP (1) EP1684719B1 (https=)
JP (1) JP2007511539A (https=)
AT (1) ATE530165T1 (https=)
AU (1) AU2004290587B2 (https=)
CA (1) CA2545855A1 (https=)
DK (1) DK1684719T3 (https=)
ES (1) ES2375706T3 (https=)
PL (1) PL1684719T3 (https=)
PT (1) PT1684719E (https=)
SI (1) SI1684719T1 (https=)
WO (1) WO2005048985A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1737499A4 (en) * 2004-03-09 2009-07-22 Arriva Pharmaceuticals Inc TREATMENT OF CHRONIC OBSTRUCTIVE LUNG DISEASE BY INHALATION OF LOW DOSES OF A PROTEASE HEMMER
EP1981572B1 (en) 2006-02-09 2012-11-21 Kamada Ltd. Pulmonary delivery of alpha-i proteinase inhibitor
EP2220115A2 (en) * 2007-12-13 2010-08-25 Glaxo Group Limited Polypeptides, antibody variable domains & antagonists
AU2010315325B2 (en) 2009-11-03 2014-11-27 Grifols Therapeutics Inc. Composition, method, and kit for alpha-1 proteinase inhibitor
PT2503995T (pt) 2009-11-24 2017-11-23 Grifols Therapeutics Inc Métodos de liofilização, composições e kits
RU2581020C2 (ru) * 2009-12-22 2016-04-10 Селлдекс Терапьютикс, Инк. Композиции вакцин
KR20140108516A (ko) 2011-12-30 2014-09-11 그리폴스, 에스.에이. 폐 악화의 발현 또는 진행을 지연시키기 위한 알파1-프로테이나제 억제제
EP2978442B1 (en) * 2013-03-29 2020-03-18 The Regents of the University of Colorado, a body corporate Alpha 1 antitrypsin of use for preparing a subject for transplant
EP3155117A4 (en) * 2014-06-11 2017-11-22 Beth Israel Deaconess Medical Center, Inc. Alpha1-antitrypsin compositions and methods of treating autoimmune diseases
WO2018116300A1 (en) * 2016-12-22 2018-06-28 Kamada Ltd. Dry powder formulations of alpha-1 antitrypsin
WO2018154568A1 (en) * 2017-02-21 2018-08-30 Kamada Ltd. Methods and uses of alpha 1-antitrypsin for early intervention in pulmonary diseases
EP3600345A4 (en) 2017-03-29 2021-01-06 Cornell University OXIDATION-RESISTANT AAT GENE THERAPY
CA3081161A1 (en) * 2017-10-31 2019-05-09 Kamada Ltd Methods and compositions for reducing lung injury associated with lung transplantation
IL267923B2 (en) * 2018-08-02 2023-06-01 Grifols Worldwide Operations Ltd The composition containing the most concentrated alpha-1 type protein inhibitor and a method for obtaining it
CA3117213A1 (en) * 2018-10-23 2020-04-30 George Edward Hoag Composition and method for treating the lungs
EP3921334A1 (en) 2019-02-08 2021-12-15 Krystal Biotech, Inc. Compositions and methods for delivering cftr polypeptides
CA3160199A1 (en) * 2019-12-20 2021-06-24 Suma Krishnan Compositions and methods for gene delivery to the airways and/or lungs
GB202102258D0 (en) * 2021-02-17 2021-03-31 Arecor Ltd Novel composition

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4150071A (en) * 1977-08-26 1979-04-17 Respiratory Care, Inc. Nebulizer
IT1105653B (it) * 1978-06-20 1985-11-04 Craighero Margherita Apparecchio aerosolizzatore
US4253468A (en) * 1978-08-14 1981-03-03 Steven Lehmbeck Nebulizer attachment
US4198969A (en) * 1978-10-06 1980-04-22 Baxter Travenol Laboratories, Inc. Suction-operated nebulizer
US4453542A (en) * 1980-12-08 1984-06-12 Vortran Corporation Vortex-generating medical products
US4775622A (en) * 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US5218091A (en) * 1982-08-13 1993-06-08 Zymogenetics, Inc. Glycolytic promoters for regulated protein expression: protease inhibitor
US5010003A (en) * 1983-04-25 1991-04-23 Genentech, Inc. Use of yeast homologous signals to secrete heterologous proteins
EP0162854A1 (en) * 1983-11-28 1985-12-04 Vortran Corporation Gas-powered nebulizer
US4711848A (en) * 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
US4940661A (en) * 1984-05-17 1990-07-10 Genentech, Inc. Metallothionein transcription control sequences and use thereof
US4931373A (en) * 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4752576A (en) * 1984-06-14 1988-06-21 Chiron Corporation Expression of α-1 antitrypsin in yeast
US4732973A (en) * 1984-06-14 1988-03-22 Chiron Corporation Active site modified protease α-1-antitrypsin inhibitors
US4837148A (en) * 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US5013652A (en) * 1986-10-14 1991-05-07 Genex Corporation Composite yeast vectors
US5093316A (en) * 1986-12-24 1992-03-03 John Lezdey Treatment of inflammation
US5166134A (en) * 1986-12-24 1992-11-24 John Lezdey Treatment of allergic rhinitis
US4839283A (en) * 1986-12-30 1989-06-13 Zymogenetics, Inc. Method of expressing alpha-1-antitrypsin in yeast
JP2656944B2 (ja) * 1987-04-30 1997-09-24 クーパー ラボラトリーズ タンパク質性治療剤のエアロゾール化
US4929555A (en) * 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US6068994A (en) * 1989-08-07 2000-05-30 Chiron Corporation Ubiquitin expression system
FR2660509B1 (fr) * 1990-03-29 1993-11-19 Alcatel Cit Etage differentiel de sortie d'equipement electronique.
US5012652A (en) * 1990-09-21 1991-05-07 Carrier Corporation Crankcase heater control for hermetic refrigerant compressors
US5134119A (en) * 1990-10-16 1992-07-28 Lezdey John Treatment of inflammation using 358 substituted alpha-antitrypsin
US5892112A (en) * 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
US5268384A (en) * 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
US5114953A (en) * 1990-11-21 1992-05-19 University Of Florida Treatment for tissue ulceration
US5256657A (en) * 1991-08-19 1993-10-26 Sterling Winthrop, Inc. Succinamide derivative matrix-metalloprotease inhibitors
TW282490B (https=) * 1992-12-15 1996-08-01 Ciba Geigy Ag
US5594106A (en) * 1993-08-23 1997-01-14 Immunex Corporation Inhibitors of TNF-α secretion
DE69528591T2 (de) * 1994-08-05 2003-02-20 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Herstellung des inhibitors fuer die komplexbildung des gewebefaktors
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5780440A (en) * 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
US6610683B2 (en) * 1996-09-12 2003-08-26 Idun Pharmaceuticals, Inc. Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
EP0911416B1 (en) * 1997-10-01 2006-05-17 DSM IP Assets B.V. Protein production process
US20010006939A1 (en) * 1997-10-03 2001-07-05 Ralph W. Niven Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
WO1999032135A1 (en) * 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
EP1047450B1 (en) * 1997-12-23 2002-10-02 Warner-Lambert Company Ace inhibitor-mmp inhibitor combinations
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
AU3511500A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
CZ20022413A3 (cs) * 2000-01-31 2003-08-13 Pfizer Products Inc. Pyrimidinkarboxamidy užitečné jako inhibitory isozymů PDE4
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US6991824B2 (en) * 2000-05-02 2006-01-31 Ventria Bioscience Expression of human milk proteins in transgenic plants
US20020099013A1 (en) * 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
US7247704B2 (en) * 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
PA8539301A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
US6544497B2 (en) * 2001-02-15 2003-04-08 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
JP2003024076A (ja) * 2001-07-12 2003-01-28 Kirin Brewery Co Ltd Ｔｐｏ変異体タンパク質
FR2832569B1 (fr) * 2001-11-22 2007-04-27 Evolium Sas Procede de transmission de communications dans un systeme de telecommunication de type cellulaire utilisant des bandes de frequences porteuses adjacentes
US20030211548A1 (en) * 2002-01-29 2003-11-13 Oncolmmunin, Inc. Visualization and quantitiation of cellular cytotoxicity using cell-permeable fluorogenic protease substrates and caspase activity indicator markers
EP1685160A1 (en) * 2003-11-10 2006-08-02 Arriva-Prometic Inc. Dry recombinant human alpha 1-antitrypsin formulation

Similar Documents

Publication Publication Date Title
JP2007511539A5 (https=)
ES2664624T3 (es) Alfa-I antitripsina para tratar episodios de exacerbación de enfermedades pulmonares
CA1327309C (en) Aerosolization of protein therapeutic agent
JP2024170583A5 (https=)
US20020127188A1 (en) Composition for pulmonary administration comprising a drug and a hydrophobic amino acid
CA3030971A1 (en) Methods for treating cystic fibrosis and other diseases affecting mucosal surfaces
Jin et al. Pulmonary delivery of the Kv1. 3-blocking peptide HsTX1 [R14A] for the treatment of autoimmune diseases
US11559498B2 (en) Compositions and methods for in vivo lung and blood SNO repletion
Ozer Alternative applications for drug delivery: Nasal and pulmonary routes
ES2928050T3 (es) Peptidomimético de horquilla beta con actividad inhibidora de elastasa y formas de dosificación en aerosol del mismo
JP2007528409A (ja) プロテアーゼインヒビターの低用量吸入による慢性閉塞性肺疾患の処置
JP2009521473A5 (https=)
JP2007511539A (ja) α１−抗トリプシン組成物およびこのような組成物を用いた処置方法
IT202000005026A1 (it) Lattoferrina per uso inalatorio ad azione antivirale
ES2791775B2 (es) Formulaciones de epinefrina intranasal y metodos para el tratamiento de enfermedades
US20070049641A1 (en) Methods for treating and monitoring inflammation and redox imbalance cystic fibrosis
CN103841958A (zh) 组合物
Kwok et al. Pulmonary delivery of peptides and proteins
CN102348465A (zh) 慢性阻塞性肺疾病改善剂
US20240009227A1 (en) Use of a heparin composition in the treatment of viral lung diseases, acute and/or chronic lung diseases by soft mist inhaler or vibration mesh technology nebulizer through inhalation route
CN105764488A (zh) 用于向受试者的气道施用酶的组合物和方法
KR20230013114A (ko) 호흡 시스템 손상 개선용 의약 조성물 및 호흡 시스템 손상 개선용 의약 조성물의 제조 용도
EP4433029B1 (en) Inhalable recombinant protein powder formulation for treating genetic and autoimmune disorders
RU2008102655A (ru) Введение в дыхательные пути ингибитора тканевого фактора при воспалительных состояниях, поражающих дыхательные пути
JP2023517480A5 (https=)